Haiyan Yang

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 183 citations

Medicine, Oncology, Pharmacology +17

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 169 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 157 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

Zhitao Ying, Haiyan Yang, Ye Guo et al. · Cancer Medicine · 2020 · 100 citations · Full text

Medicine, Clinical Pharmacokinetics, Oncology +17

Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis

Shengbing Zang, Jia Li, Haiyan Yang et al. · Journal of Clinical Investigation · 2017 · 95 citations · Full text

Medicine, Genetics, Immunology +15